Comparison · NCT02300233-0cf69725
Volanesorsen Total vs Placebo: Treatment Response Rate Defined as Participants With Fasting TG ≥ 40% Reduction From Baseline at Month 3
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Volanesorsen Total vs Placebo: Treatment Response Rate Defined as Participants With Fasting TG ≥ 40% Reduction From Baseline at Month 3. Trial comparisons, record NCT02300233-0cf69725. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02300233-0cf69725
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.867 | 0.772 | 0.926 | wilson | |
| Risk in group 2 | 0.132 | 0.0575 | 0.273 | wilson | |
| Risk difference, group 1 minus group 2 | 0.735 | 0.564 | 0.83 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 6.59 | 2.9 | 15 | log | |
| Odds ratio, group 1 over group 2 | 42.9 | 13.6 | 136 | log | |
| Number needed to treat, for one more participant with the outcome on Volanesorsen Total than on Placebo | 1.36 | 1.2 | 1.77 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Volanesorsen Total | Volanesorsen 300 mg administered subcutaneously once-weekly for 26 weeks; or once-weekly for 13 weeks, then bi-weekly for 13 weeks. | 65 | 75 | OG001 |
| Group 2 | Placebo | Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks. | 5 | 38 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Treatment Response Rate Defined as Participants With Fasting TG ≥ 40% Reduction From Baseline at Month 3
- Description
- Time frame
- Baseline to 3 months
- Population
- The FAS included all participants who were randomized, received at least one dose of study drug, and had a baseline TG assessment.
Source ClinicalTrials.gov
Trial
- Title
- The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
- NCT number
- NCT02300233
- Phases
- PHASE3
- Conditions
- Hypertriglyceridemia
- Interventions
- Volanesorsen, Placebo
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Results first posted
- 2022-04-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02300233?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02300233-0cf69725